Werewolf Therapeutics Net Worth
Werewolf Therapeutics Net Worth Breakdown | HOWL |
Werewolf Therapeutics Net Worth Analysis
Werewolf Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Werewolf Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Werewolf Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Werewolf Therapeutics' net worth analysis. One common approach is to calculate Werewolf Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Werewolf Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Werewolf Therapeutics' net worth. This approach calculates the present value of Werewolf Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Werewolf Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Werewolf Therapeutics' net worth. This involves comparing Werewolf Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Werewolf Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Werewolf Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Werewolf Therapeutics' net worth research are outlined below:
| Werewolf Therapeutics had very high historical volatility over the last 90 days | |
| Werewolf Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 19.94 M. Net Loss for the year was (37.37 M) with loss before overhead, payroll, taxes, and interest of (37.36 M). | |
| Werewolf Therapeutics currently holds about 145.71 M in cash with (32.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference |
Werewolf Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Werewolf Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Werewolf Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Werewolf Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Werewolf Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Werewolf Therapeutics backward and forwards among themselves. Werewolf Therapeutics' institutional investor refers to the entity that pools money to purchase Werewolf Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 686 K | Sphera Funds Management Ltd. | 2024-09-30 | 626.8 K | Dc Funds, Lp | 2024-09-30 | 589.1 K | State Street Corp | 2024-06-30 | 423.9 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 257.8 K | Two Sigma Advisers, Llc | 2024-06-30 | 239.3 K | Alyeska Investment Group, L.p. | 2024-09-30 | 235.7 K | Verition Fund Managegment, Llc | 2024-06-30 | 233.8 K | Northern Trust Corp | 2024-09-30 | 227.8 K | Ra Capital Management, Llc | 2024-09-30 | 6.1 M | Mpm Asset Management, Llc | 2024-09-30 | 4.3 M |
Follow Werewolf Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 84.67 M.Market Cap |
|
Project Werewolf Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.26) | (0.27) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.34) | (0.32) |
When accessing Werewolf Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Werewolf Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Werewolf Therapeutics' profitability and make more informed investment decisions.
Evaluate Werewolf Therapeutics' management efficiency
Werewolf Therapeutics has return on total asset (ROA) of (0.2616) % which means that it has lost $0.2616 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6156) %, meaning that it created substantial loss on money invested by shareholders. Werewolf Therapeutics' management efficiency ratios could be used to measure how well Werewolf Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.22. The value of Return On Capital Employed is expected to slide to -0.27. At this time, Werewolf Therapeutics' Net Tangible Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 38.3 M this year, although the value of Other Assets will most likely fall to 0.95.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.12 | 1.65 | |
| Tangible Book Value Per Share | 3.12 | 1.65 | |
| Enterprise Value Over EBITDA | (1.70) | (1.78) | |
| Price Book Value Ratio | 1.24 | 1.30 | |
| Enterprise Value Multiple | (1.70) | (1.78) | |
| Price Fair Value | 1.24 | 1.30 | |
| Enterprise Value | 63.5 M | 60.3 M |
Effective management at Werewolf Therapeutics has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Enterprise Value Revenue 0.6742 | Revenue 3.4 M | Quarterly Revenue Growth (0.86) | Revenue Per Share 0.082 | Return On Equity (0.62) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Werewolf Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Werewolf Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Werewolf Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Werewolf Therapeutics time-series forecasting models is one of many Werewolf Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Werewolf Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Werewolf Therapeutics Earnings per Share Projection vs Actual
Werewolf Therapeutics Corporate Management
| Randi MD | Chief Officer | Profile | |
| Timothy CPA | Treasurer CFO | Profile | |
| Cynthia SeidelDugan | Chief Officer | Profile | |
| Ellen MBA | Chief Officer | Profile | |
| Daniel Hicklin | CEO, Founder | Profile | |
| William Winston | Senior Research | Profile | |
| Chulani Karunatilake | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.082 | Quarterly Revenue Growth (0.86) | Return On Assets (0.26) | Return On Equity (0.62) |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.